Last reviewed · How we verify
PI
PI is a protease inhibitor that blocks viral protease activity, preventing the maturation and replication of viruses.
At a glance
| Generic name | PI |
|---|---|
| Also known as | Fosamprenavir, atazanavir, lopinavir or darunavir |
| Sponsor | Hoffmann-La Roche |
| Drug class | Protease inhibitor |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Protease inhibitors bind to the active site of viral proteases, enzymes essential for processing viral polyproteins into functional components. By inhibiting this enzymatic activity, the drug prevents the production of infectious viral particles. This class has been widely used in treating HIV and hepatitis C infections.
Approved indications
Common side effects
Key clinical trials
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (PHASE2)
- A Study of a Weight Loss Intervention in People With Endometrial Cancer (EARLY_PHASE1)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes
- Salivary and Serum Inflammatory Biomarkers in Diabetic Nephropathy by Periodontal Status
- Target of Suv420h1/2 in Hepatocytes (NA)
- A Clinical Investigation of the Decoria® Aesthetic Group (DAG) for Correction of Nasolabial Folds (NLF) (NA)
- Neuromodulation With Percutaneous Electrical Nerve Field Stimulation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |